Roche Glycart Ag

Other

Glycart Biotechnology Ag

Cytos Biotechnology Ag

Roche Glyeart Ag

Solidago Ag

Cistronics Cell Technology Gmbh

Cytos Biotechnology

James E Bailey

Pablo Umaña

Joël Jean-Mairet

Wolfgang Andreas Renner

Martin Fussenegger

Georg H Orberger

Daniel Koller

Pablo Umana

M Sean Bailey, Legal Representative

Jo&euml;l Jean-Mairet

Pablo Uma&ntilde;a

Joel Jean-Mairet

Charles J Thompson

Hans M Eppenberger

Leif Bulow

Pauli Kallio

Wolfgang Minas

Peter Brunker

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

The present invention is directed to a method for detection, characterization and isolation of nucleic acids encoding proteins of a desired property, such as a particular cellular localization. The invention further provides for rapid expression of such proteins or glycoproteins in mammalian cells and for facilitated purification of the novel secreted proteins or glycoproteins. Further, the invention provides for radioactive labelling of the novel proteins or glycoproteins, for rapid identification of sites of binding including animals and for rapid production of infective viral vectors for use in gene transfer.

Expression cloning processes for the discovery, characterization and isolation of genes encoding polypeptides with a predetermined property

The invention relates to a novel system for gene regulation in eukaryotic cells, and methods of using the same for protein production, tissue engineering and gene therapy. In particular, the invention provides a new system for antibiotic-regulated gene expression in eukaryotic cells based on sequences from Actinomycetes antibiotic resistance promoters, polypeptides that bind to the same in an antibiotic responsive manner, and nucleotides encoding such polypeptides. Further, the invention provides novel and sensitive methods of screening for candidate antibiotics.

Antibiotic-based gene regulation system

Provided by the invention are novel methods, vectors and cells for the recombinant production of desired gene products. In particular, the invention relates to increased production of desired gene products by inducibly arresting cell proliferation. The invention also provides novel multicistronic expression vectors that are useful not only for recombinant gene expression, but also for other applications such as gene therapy, tissue engineering and metabolic engineering.

Cytostatic process increases the productivity of cultured cells

Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property

Growing community of inventors

Zurich, Switzerland

James E Bailey